Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Cancer research - 1 Sept 2010

Halilovic Ensar, She Qing-Bai, Ye Qing, Pagliarini Raymond, Sellers William R, Solit David B, Rosen Neal

Abstract excerpt

Mutational activation of KRAS is a common event in human tumors. Identification of the key signaling pathways downstream of mutant KRAS is essential for our understanding of how to pharmacologically target these cancers in patients. We show that PD0325901, a small-molecule MEK inhibitor, decreases MEK/ERK pathway signaling and destabilizes cyclin D1, resulting in significant anticancer activity in a subset of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cell Growth Processes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Cyclin D1

Share to Extracellular Signal-Regulated MAP Kinases

Share to HCT116 Cells

Share to MAP Kinase Kinase Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 20699365
DOI: 10.1158/0008-5472.CAN-10-0409
PMCID: PMC3178450

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.PMID 20699365Read ↗

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.Semantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumorsSemantic proximity Read ↗

BRAF mutation predicts sensitivity to MEK inhibition.Semantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor ResistanceSemantic proximity Read ↗

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.Semantic proximity Read ↗

RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.Semantic proximity Read ↗

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Semantic proximity Read ↗

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.Semantic proximity Read ↗

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survivalSemantic proximity Read ↗

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.